BBIO Stock Analysis: Buy, Sell, or Hold?
BBIO - BridgeBio Pharma, Inc. Common Stock
$81.50
-1.44 (-1.74%)
âŧ
5d:
+2.05%
30d:
-1.72%
90d:
+15.96%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When BBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BBIO is fairly priced but lacks strong directional signals. At 40.4% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BBIO is fairly priced but lacks strong directional signals. At 40.4% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: BBIO is currently trading at $81.50, which is considered slightly low relative to its 30-day fair value range of $80.98 to $84.06. From a valuation perspective, the stock is trading at a premium (Forward PE: 532.0) compared to its historical average (192.3). At these levels, the market is pricing in 40.4% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, BBIO is in a strong uptrend. Immediate support is located at $78.12, while resistance sits at $89.49.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $108.43 (+33.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BBIO is in a strong uptrend. Immediate support is located at $78.12, while resistance sits at $89.49.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $108.43 (+33.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$80.98 -
$84.06
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding BBIO? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 33.0% below Wall St target ($108.43)
- BEARISH: Market expects 40.4% growth - appears too optimistic based on history
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$80.98 -
$84.06
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$78.13
Resistance Level
$89.49
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
531.98
Wall Street Target
$108.43
(+33.0%)
Revenue Growth (YoY)
120.4%
Profit Margin
-97.0%
Valuation Premium vs History
+40.4% premium
PE vs Historical
532.0 vs 192.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+40.4%
(market-implied from PE analysis)
1-Year Target
$114.43
(+40%)
2-Year Target
$160.65
(+97%)
3-Year Target
$225.56
(+177%)
3-Yr Target (if PE normalizes)
(PE: 532â192)
PE COMPRESSION
$81.53
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 23, 2026 11:00 AM ET
Data refreshes hourly during market hours. Next update: 12:00 PM
Data refreshes hourly during market hours. Next update: 12:00 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BBIO showing a specific setup today?
Insider Activity (6 Months)
3
Buys
3
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Neil Kumar
SELL
40000 shares
2026-04-09
Gilbert Ray Cisneros, Jr.
BUY
2026-03-19
Gilbert Ray Cisneros, Jr.
BUY
2026-03-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 35 SELL |
Advanced BBIO Option Strategies
Professional options setups generated by AI based on today's BBIO price and gamma walls.
